Intracellular secretory leukoprotease inhibitor modulates inositol 1,4,5-triphosphate generation and exerts an anti-inflammatory effect on neutrophils of individuals with cystic fibrosis and chronic obstructive pulmonary disease

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Reeves, Emer P ^a   Banville, Nessa ^a   Ryan, Dorothy M ^a   O'Reilly, Niamh ^a   Bergin, David A ^a   Pohl, Kerstin ^a   Molloy, Kevin ^a   McElvaney, Oliver J ^a   Alsaleh, Khalifah ^a   Aljorfi, Ahmed ^a   Kandalaft, Osama ^a   O'Flynn, Eimear ^a   Geraghty, Patrick ^a   O'Neill, Shane J ^a   McElvaney, Noel G ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

FORMYLMETHIONYLLEUCYLPHENYLALANINE; GELATINASE B; INOSITOL 1,4,5 TRISPHOSPHATE; INTERLEUKIN 8; MYELOPEROXIDASE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; ANTIINFLAMMATORY AGENT; CALCIUM; IMMUNOLOGIC FACTOR; RECOMBINANT PROTEIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM TRANSPORT; CELL ISOLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DEGRANULATION; DRUG MECHANISM; ELECTROPORATION; FEMALE; HUMAN; HUMAN CELL; MALE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; BIOLOGICAL MODEL; BIOSYNTHESIS; CHEMOTAXIS; CYTOSKELETON; CYTOSOL; DRUG EFFECT; INTRACELLULAR SPACE; LEUKOCYTE ACTIVATION; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY; DRUG EFFECTS;

ADULT; ANTI-INFLAMMATORY AGENTS; CALCIUM; CELL DEGRANULATION; CHEMOTAXIS; CYSTIC FIBROSIS; CYTOSKELETON; CYTOSOL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR SPACE; MALE; MODELS, BIOLOGICAL; NEUTROPHIL ACTIVATION; NEUTROPHILS; OXIDATION-REDUCTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOMBINANT PROTEINS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR;

EID: 84884253701     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/560141     Document Type: Article

References (63)

1. Gabrilovich D. I., The Neutrophils: New Outlook for Old Cells 2005 2nd Imperial College Press
2. Pollard T. D., Cooper J. A., Actin, a central player in cell shape and movement. Science 2009 326 5957 1208 1212 2-s2.0-70849098888 10.1126/science.1175862
3. Tintinger G., Steel H. C., Anderson R., Taming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control. Clinical and Experimental Immunology 2005 141 2 191 200 2-s2.0-22344443770 10.1111/j.1365-2249.2005.02800.x
4. Bokoch G. M., Chemoattractant signaling and leukocyte activation. Blood 1995 86 5 1649 1660 2-s2.0-0029099616
5. Binah O., Shilkrut M., Yaniv G., Larisch S., The Fas receptor 1,4,5-IP3 cascade: a potential target for treating heart failure and arrhythmias. Annals of the New York Academy of Sciences 2004 1015 338 350 2-s2.0-3042833684 10.1196/annals.1302.030
6. Wacker M. J., Kosloski L. M., Gilbert W. J. R., Touchberry C. D., Moore D. S., Kelly J. K., Brotto M., Orr J. A., Inhibition of thromboxane A2-induced arrhythmias and intracellular calcium changes in cardiac myocytes by blockade of the inositol trisphosphate pathway. Journal of Pharmacology and Experimental Therapeutics 2009 331 3 917 924 2-s2.0-73349134301 10.1124/jpet.109.157677
7. Vogelmeier C., Buhl R., Hoyt R. F., Wilson E., Fells G. A., Hubbard R. C., Schnebli H. P., Thompson R. C., Crystal R. G., Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. Journal of Applied Physiology 1990 69 5 1843 1848 2-s2.0-0025640798
8. Birrer P., Mcelvaney N. G., Rüdeberg A., Wirz Sommer C., Liechti-Gallati S., Kraemer R., Hubbard R., Crystal R. G., Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1994 150 1 207 213 2-s2.0-0028240276
9. Suter S., The imbalance between granulocyte neutral proteases and antiproteases in bronchial secretions from patients with cystic fibrosis. Antibiotics and Chemotherapy 1989 42 158 168 2-s2.0-0024839280
10. Schalkwijk J., Wiedow O., Hirose S., The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochemical Journal 1999 340 part 3 569 577 2-s2.0-0033564267 10.1042/0264-6021:3400569
11. Sallenave J. M., Har M. S. T., Cox G., Chignard M., Gauldie J., Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. Journal of Leukocyte Biology 1997 61 6 695 702 2-s2.0-0030977618
12. Greene C. M., McElvaney N. G., O'Neill S. J., Taggart C. C., Secretory leucoprotease inhibitor impairs toll-like receptor 2- and 4-mediated responses in monocytic cells. Infection and Immunity 2004 72 6 3684 3687 2-s2.0-2542533920 10.1128/IAI.72.6.3684-3687.2004
13. Taggart C. C., Greene C. M., McElvaney N. G., O'Neill S., Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced I B α degradation without affecting phosphorylation or ubiquitination. Journal of Biological Chemistry 2002 277 37 33648 33653 2-s2.0-0037072766 10.1074/jbc.M203710200
14. Ding A., Thieblemont N., Zhu J., Jin F., Zhang J., Wright S., Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages. Infection and Immunity 1999 67 9 4485 4489 2-s2.0-0032773727
15. McMichael J. W., Roghanian A., Jiang L., Ramage R., Sallenave J. M., The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. American Journal of Respiratory Cell and Molecular Biology 2005 32 5 443 452 2-s2.0-18244405296 10.1165/rcmb.2004-0250OC
16. Jacobsen L. C., Sørensen O. E., Cowland J. B., Borregaard N., Theilgaard-Mönch K., The secretory leukocyte protease inhibitor (SLPI) and the secondary granule protein lactoferrin are synthesized in myelocytes, colocalize in subcellular fractions of neutrophils, and are coreleased by activated neutrophils. Journal of Leukocyte Biology 2008 83 5 1155 1164 2-s2.0-46949103677 10.1189/jlb.0706442
17. Segal A. W., Jones O. T. G., Rapid incorporation of the human neutrophil plasma membrane cytochrome b into phagocytic vacuoles. Biochemical and Biophysical Research Communications 1980 92 2 710 715 2-s2.0-0018896860
18. Bergin D. A., Reeves E. P., Meleady P., Henry M., McElvaney O. J., Carroll T. P., Condron C., Chotirmall S. H., Clynes M., O'Neill S. J., McElvaney N. G., α -1 antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. Journal of Clinical Investigation 2010 120 12 4236 4250 2-s2.0-78649816539 10.1172/JCI41196
19. Jayachandran R., Sundaramurthy V., Combaluzier B., Mueller P., Korf H., Huygen K., Miyazaki T., Albrecht I., Massner J., Pieters J., Survival of Mycobacteria in Macrophages Is Mediated by Coronin 1-Dependent Activation of Calcineurin. Cell 2007 130 1 37 50 2-s2.0-34447102567 10.1016/j.cell.2007.04.043
20. Taggart C. C., Cryan S. A., Weldon S., Gibbons A., Greene C. M., Kelly E., Low T. B., O'Neill S. J., McElvaney N. G., Secretory leucoprotease inhibitor binds to NF- B binding sites in monocytes and inhibits p65 binding. Journal of Experimental Medicine 2005 202 12 1659 1668 2-s2.0-29144439305 10.1084/jem.20050768
21. Birrer P., McElvaney N. G., Gillissen A., Hoyt R. F., Bloedow D. C., Hubbard R. C., Crystal R. G., Intravenous recombinant secretory leukoprotease inhibitor augments antineutrophil elastase defense. Journal of Applied Physiology 1992 73 1 317 323 2-s2.0-0026769518
22. McNeely T. B., Dealy M., Dripps D. J., Orenstein J. M., Eisenberg S. P., Wahl S. M., Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus I activity in vitro. Journal of Clinical Investigation 1995 96 1 456 464 2-s2.0-0029115952
23. Herrero-Turrión M. J., Calafat J., Janssen H., Fukuda M., Mollinedo F., Rab27a regulates exocytosis of tertiary and specific granules in human neutrophils. Journal of Immunology 2008 181 6 3793 3803 2-s2.0-56149103148
24. Niessen H. W. M., Verhoeven A. J., Differential up-regulation of specific and azurophilic granule membrane markers in electropermeabilized neutrophils. Cellular Signalling 1992 4 5 501 509 2-s2.0-0026733319 10.1016/0898-6568(92) 90019-5
25. Weathington N. M., Van Houwelingen A. H., Noerager B. D., Jackson P. L., Kraneveld A. D., Galin F. S., Folkerts G., Nijkamp F. P., Blalock J. E., A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nature Medicine 2006 12 3 317 323 2-s2.0-33644828187 10.1038/nm1361
26. Bergsson G., Reeves E. P., McNally P., Chotirmall S. H., Greene C. M., Greally P., Murphy P., O'Neill S. J., McElvaney N. G., LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. Journal of Immunology 2009 183 1 543 551 2-s2.0-68949117860 10.4049/jimmunol.0803959
27. Peres C. M., Aronoff D. M., Serezani C. H., Flamand N., Faccioli L. H., Peters-Golden M., Specific leukotriene receptors couple to distinct G proteins to effect stimulation of alveolar macrophage host defense functions. Journal of Immunology 2007 179 8 5454 5461 2-s2.0-38449104856
28. Anton P., O'Connell J., O'Connell D., Whitaker L., O'Sullivan G. C., Collins J. K., Shanahan F., Mucosal subepithelial binding sites for the bacterial chemotactic peptide, formyl-methionyl-leucyl-phenylalanine (FMLP). Gut 1998 42 3 374 379 2-s2.0-0031957984
29. Henriksen P. A., Hitt M., Xing Z., Wang J., Haslett C., Riemersma R. A., Webb D. J., Kotelevtsev Y. V., Sallenave J. M., Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF- B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. Journal of Immunology 2004 172 7 4535 4544 2-s2.0-1642316460
30. Guerrieri D., Tateosian N. L., Maffía P. C., Reiteri R. M., Amiano N. O., Costa M. J., Villalonga X., Sanchez M. L., Estein S. M., Garcia V. E., Sallenave J. M., Chuluyan H. E., Serine leucocyte proteinase inhibitor-treated monocyte inhibits human CD4+ lymphocyte proliferation. Immunology 2011 133 4 434 441 2-s2.0-79959911311 10.1111/j.1365-2567.2011.03451.x
31. Tiringer K., Treis A., Fucik P., Gona M., Gruber S., Renner S., Dehlink E., Nachbaur E., Horak F., Jaksch P., Döring G., Crameri R., Jung A., Rochat M. K., Hörmann M., Spittler A., Klepetko W., Akdis C. A., Szépfalusi Z., Frischer T., Eiwegger T., A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. American Journal of Respiratory and Critical Care Medicine 2012 187 6 621 629
32. Hoetzenecker K., Mitterbauer A., Guenova E., Schweiger T., Altmann P., Zimmermann M., Hofbauer H., Beer L., Klepetko W., Ankersmit H. J., High levels of lung resident CD4+CD28null cells in COPD: implications of autoimmunity. Wien Klin Wochenschr 2013 125 5-6 150 155 10.1007/s00508-013-0340-4
33. Chotirmall S. H., Greene C. M., Oglesby I. K., Thomas W., O'Neill S. J., Harvey B. J., McElvaney N. G., 17 β -estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor. American Journal of Respiratory and Critical Care Medicine 2010 182 1 62 72 2-s2.0-77955916914 10.1164/rccm.201001-0053OC
34. Thompson R. C., Ohlsson K., Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proceedings of the National Academy of Sciences of the United States of America 1986 83 18 6692 6696 2-s2.0-0012030796
35. Ma G., Greenwell-Wild T., Lei K., Jin W., Swisher J., Hardegen N., Wild C. T., Wahl S. M., Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. Journal of Experimental Medicine 2004 200 10 1337 1346 2-s2.0-9244260537 10.1084/jem.20041115
36. Py B., Basmaciogullari S., Bouchet J., Zarka M., Moura I. C., Benhamou M., Monteiro R. C., Hocini H., Madrid R., Benichou S., The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane. PLoS ONE 2009 4 3 2-s2.0-63749116310 10.1371/journal.pone.0005006 e5006
37. Kaneider N. C., Rabensteiner A., Reinisch C. M., Dunzendorfer S., Wiedermann C. J., Inhibition of human neutrophil chemotaxis toward interleukin 8 with six clinical antithrombin concentrates in vitro. Intensive Care Medicine 2002 28 10 1447 1452 2-s2.0-0036390175 10.1007/s00134-002-1432-1
38. McHugh D., Tanner C., Mechoulam R., Pertwee R. G., Ross R. A., Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Molecular Pharmacology 2008 73 2 441 450 2-s2.0-38549130466 10.1124/mol.107.041863
39. Petit-Bertron A. F., Tabary O., Corvol H., Jacquot J., Clément A., Cavaillon J. M., Adib-Conquy M., Circulating and airway neutrophils in cystic fibrosis display different TLR expression and responsiveness to interleukin-10. Cytokine 2008 41 1 54 60 2-s2.0-37449031035 10.1016/j.cyto.2007.10.012
40. Pedersen S. S., Kharazmi A., Espersen F., Hoiby N., Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infection and Immunity 1990 58 10 3363 3368 2-s2.0-0025006851
41. Koller D. Y., Urbanek R., Gotz M., Increased degranulation of eosinophil and neutrophil granulocytes in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1995 152 2 629 633 2-s2.0-0029126156
42. Taggart C., Coakley R. J., Greally P., Canny G., O'Neill S. J., McElvaney N. G., Increased elastase release by CF neutrophils is mediated by tumor necrosis factor- α and interleukin-8. American Journal of Physiology 2000 278 1 L33 L41 2-s2.0-0033962098
43. Borregaard N., Sørensen O. E., Theilgaard-Mönch K., Neutrophil granules: a library of innate immunity proteins. Trends in Immunology 2007 28 8 340 345 2-s2.0-34447561633 10.1016/j.it.2007.06.002
44. Franco S. J., Rodgers M. A., Perrin B. J., Han J., Bennin D. A., Critchley D. R., Huttenlocher A., Calpain-mediated proteolysis of talin regulates adhesion dynamics. Nature Cell Biology 2004 6 10 977 983 2-s2.0-5444239061 10.1038/ncb1175
45. Yuruker B., Niggli V., α -Actinin and vinculin in human neutrophils: reorganization during adhesion and relation to the actin network. Journal of Cell Science 1992 101 2 403 414 2-s2.0-0026573490
46. Huttenlocher A., Palecek S. P., Lu Q., Zhang W., Mellgren R. L., Lauffenburger D. A., Ginsberg M. H., Horwitz A. F., Regulation of cell migration by the calcium-dependent protease calpain. Journal of Biological Chemistry 1997 272 52 32719 32722 2-s2.0-0031455371 10.1074/jbc.272.52.32719
47. Eisenberg S. P., Hale K. K., Heimdal P., Thompson R. C., Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. Journal of Biological Chemistry 1990 265 14 7976 7981 2-s2.0-0025274374
48. Petrache I., Fijalkowska I., Medler T. R., Skirball J., Cruz P., Zhen L., Petrache H. I., Flotte T. R., Tuder R. M., α -1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. American Journal of Pathology 2006 169 4 1155 1166 2-s2.0-34248658381 10.2353/ajpath.2006.060058
49. Al-Omari M., Korenbaum E., Ballmaier M., Lehmann U., Jonigk D., Manstein D. J., Welte T., Mahadeva R., Janciauskiene S., Acute-phase protein α 1-antitrypsin inhibits neutrophil calpain I and induces random migration. Molecular Medicine 2011 17 9-10 865 874 2-s2.0-84858699084
50. Bokoch G. M., Chemoattractant signaling and leukocyte activation. Blood 1995 86 5 1649 1660 2-s2.0-0029099616
51. Krause K. H., Schlegel W., Wollheim C. B., Chemotactic peptide activation of human neutrophils and HL-60 cells. Pertussis toxin reveals correlation between inositol trisphosphate generation, calcium ion transients, and cellular activation. Journal of Clinical Investigation 1985 76 4 1348 1354 2-s2.0-0022347782
52. Schorr W., Swandulla D., Zeilhofer H. U., Mechanisms of IL-8-induced Ca2+ signaling in human neutrophil granulocytes. European Journal of Immunology 1999 29 3 897 904 2-s2.0-0033024882
53. Chen L. W., Lin M. W., Hsu C. M., Different pathways leading to activation of extracellular signal-regulated kinase and p38 MAP kinase by formyl-methionyl-leucyl-phenylalanine or platelet activating factor in human neutrophils. Journal of Biomedical Science 2005 12 2 311 319 2-s2.0-21244504902 10.1007/s11373-005-1704-1
54. McLeish K. R., Knall C., Ward R. A., Gerwins P., Coxon P. Y., Klein J. B., Johnson G. L., Activation of mitogen-activated protein kinase cascades during priming of human neutrophils by TNF- α and GM-CSF. Journal of Leukocyte Biology 1998 64 4 537 545 2-s2.0-0031662161
55. Wang Y. H., Wang W. Y., Liao J. F., Chen C. F., Hou Y. C., Liou K. T., Chou Y. C., Tien J. H., Shen Y. C., Prevention of macrophage adhesion molecule-1 (Mac-1)-dependent neutrophil firm adhesion by taxifolin through impairment of protein kinase-dependent NADPH oxidase activation and antagonism of G protein-mediated calcium influx. Biochemical Pharmacology 2004 67 12 2251 2262 2-s2.0-2442547470 10.1016/j.bcp.2004.02.020
56. Al-Mohanna F., Saleh S., Parhar R. S., Collison K., IL-12-dependent nuclear factor- B activation leads to de novo synthesis and release of IL-8 and TNF- α in human neutrophils. Journal of Leukocyte Biology 2002 72 5 995 1002 2-s2.0-0036855659
57. Hou C., Kirchner T., Singer M., Matheis M., Argentieri D., Cavender D., In vivo activity of a phospholipase C inhibitor, 1-(6-((17 β -3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione (U73122), in acute and chronic inflammatory reactions. Journal of Pharmacology and Experimental Therapeutics 2004 309 2 697 704 2-s2.0-2142717337 10.1124/jpet.103.060574
58. Konstan M. W., Davis P. B., Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Advanced Drug Delivery Reviews 2002 54 11 1409 1423 2-s2.0-0037027948 10.1016/S0169-409X(02)00146-1
59. McElvaney N. G., Doujaiji B., Moan M. J., Burnham M. R., Wu M. C., Crystal R. G., Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. American Review of Respiratory Disease 1993 148 4, part 1 1056 1060 2-s2.0-0027495712
60. Gast A., Anderson W., Probst A., Nick H., Thompson R. C., Eisenberg S. P., Schnebli H., Pharmacokinetics and distribution of recombinant secretory leukocyte proteinase inhibitor in rats. American Review of Respiratory Disease 1990 141 4, part 1 889 894 2-s2.0-0025233869
61. Heyworth P. G., Curnutte J. T., Nauseef W. M., Volpp B. D., Pearson D. W., Rosen H., Clark R. A., Neutrophil nicotinamide adenine dinucleotide phosphate oxidase assembly. Translocation of p47-phox and p67-phox requires interaction between p47-phox and cytochrome b558. Journal of Clinical Investigation 1991 87 1 352 356 2-s2.0-0025970033
62. Gibbons A. M., McElvaney N. G., Taggart C. C., Cryan S. A., Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. Journal of Microencapsulation 2009 26 6 513 522 2-s2.0-70849090983 10.1080/02652040802466535
63. Barros S. C., Martins J. A., Marcos J. C., Cavaco-Paulo A., Influence of secretory leukocyte protease inhibitor-based peptides on elastase activity and their incorporation in hyaluronic acid hydrogels for chronic wound therapy. Biopolymers 2012 98 6 576 590 10.1002/bip.22166